APH Falls And Anonymous Shorts

Since July 9th Clarus purchased $7,067,826 Net Invested prior to this rotten red day for Aphria.  And $3,497,685 .00 of that was in the last week

Do you think a lead underwriter would be privy to the 6 cent loss?

20180730

0

14,000

155,871

11.134

-14,000

318,100

155,871

Net Buys $3,497,685

So why would they take that money and now have a huge loss?
They were supporting their client who paid them a commission of 
Clarus Commission $12,290,662.72 ( due to over-allotment) 

Short Positions for APH

Symbol	Report Date	Volume	Change	Shares Issued	% Float
T : APH	2018-07-15	5,750,974	-1,157,648	232,005,434	2.48
T : APH	2018-06-30	6,908,622	-6,411,236	232,005,434	2.98
T : APH	2018-06-15	13,319,858	7,472,958	210,125,411	6.34

So did ANONYMOUS sell short today? 
We wont know until August 15th report on short sales.


Aphria Inc. is pleased to announce it has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' over-allotment option. A total of 21,835,510 common shares of the Company were sold at a price of $11.85 per Share, for aggregate gross proceeds of $258,750,794. 

Clarus Securities Inc. and included Canaccord Genuity Corp., Cormark Securities Inc., Haywood Securities Inc. and  INFOR Financial Inc. (collectively, the “Underwriters“).Price: $11.85 per Common Share Price to the Underwriters’ Net Proceeds to Public(1) Fee(2) the Company(3) Per Offered Share .............................. $11.85
$0.5629 $11.2871 Total ....................................... $225,000,690

Clarus Commission $12,290,662.72 ( due to over-allotment) 
and other brokerages as Clarus has privately negotiated.

NET PROCEEDS TO COMPANY $214,313,157.22

The Underwriters have been granted an over-allotment option, exercisable, in whole or in part, at the sole discretion of the Underwriters, for a period of 30 days from and including the Closing Date, to purchase up to an additional 2,848,110 Offered Shares (the ‘‘Over-Allotment Shares’’) at the Offering Price to cover the Underwriters’ over-allocation position, if any, and for market stabilization purposes (the ‘‘Over-Allotment Option’’). If the Over-Allotment Option is exercised in full, the total ‘‘Price to the Public’’, ‘‘Underwriters’ Fee’’ and ‘‘Net Proceeds to the Company’’ will be $258,750,794, Commission $12,290,662.72 and $246,460,131.28, respectively. This Prospectus qualifies the grant of the Over-Allotment Option and the distribution of the Over-Allotment Shares issuable upon exercise of the Over-Allotment Option. A purchaser who acquires Over-Allotment Shares forming part of the Underwriters’ over-allocation position acquires those Over-Allotment Shares under this Prospectus, regardless of whether the over-allocation position is ultimately filled through the exercise of the Over-Allotment Option or secondary market purchases. S

https://aphria.ca/press-releases/

Events:

1. $225 Million private placement dilution (under water 11,85-today)
2. Delays Financials to coincide with Molson August 1 release of financials- Takeover?
3. Coincidence? Bullboard Pump Rumours fly...takeover or (JV)Joint Venture
4. Coors in talks:Cannabis companies 
5. Aphria a leading top 3.
6. Vic  announces line of credit with Credit Union 25 Million 
7. (2nd time since May 9, 2017)
8. Coors partners with HEXO 
9. Aphria Loses .06 cents per share in the 4th quarter= $13,920,326.04
10. Aphria Tanks August 1 2018

Market Punishes APH and Shareholders Holding The Bag.


Aphria Inc. has secured $25-million in debt financing from WFCU Credit Union. The five-year term loan bears interest at 4.68 per cent, has a 15-year amortization and was entered into on July 27, 2018. This is the second round of debt financing secured by the company from WFCU, having previously secured a $25-million five-year loan on May 9, 2017.
https://aphria.ca/

"We are delighted to once again have the support of WFCU Credit Union as Aphria continues to execute on its long-term strategic plan," said Vic Neufeld, chief executive officer at Aphria. "Our diversified approach to innovation, strategic partnerships and global expansion are driving long-term shareholder value, and as our company and industry evolve we are always looking for opportunities to normalize our debt-to-equity structure."

Lead Underwriter 
Clarus bets $7,067,826.00 Dollars 

Fundamental Data - APH

Security Type	Equity
Shares Issued	232,005,434
Market Cap	2,670,383,000
Year High	24.75
Year Low	5.62
Annual Earnings/Share	0.20 CAD
P/E Ratio	57.55
Annual Dividend/Share	0.00 CAD
Annual Dividend Yield	0.00 %
Ex-Dividend Date
Sector	30202010 - Agricultural Products

Did you see this coming? Neither did we...but we sold yesterday .

The strong support levels are $9.63 and $8.90 see the fine print below showing those amounts.  Thats the two bottoms that could be tested, then worst case far far below is $8.10 and $6.31. 
But $8.90 seems possible before Oct 17.

Because nothing will happen leading up to Oct 17 nothing as important as the last 2 impending events they just screwed up. 

So now what? 

Sell and use the cash to look for a bottom closer to those numbers. Its going down folks...might as well buy it cheaper.

And then of course there is others like HEXO and that is another story.

BIGGEST SELLING RETAIL THE SHARES

89 Raymond James	129,002	1,390,695	10.78	152,651	1,652,290	10.824	-23,649	261,595
74 GMP	0			63,206	682,907	10.804	-63,206	682,907
13 Instinet	102,465	1,102,385	10.759	169,000	1,825,036	10.799	-66,535	722,651
33 Canaccord	97,429	1,055,599	10.835	173,705	1,888,364	10.871	-76,276	832,765
39 Merrill Lynch	184,075	1,985,688	10.787	273,561	2,945,338	10.767	-89,486	959,650
1 Anonymous	1,390,235	15,030,970	10.812	1,540,636	16,633,808	10.797	-150,401	1,602,838
53 Morgan Stanley	28,602	308,573	10.789	333,015	3,583,185	10.76	-304,413	3,274,612
79 CIBC	1,487,919	16,040,231	10.78	1,797,986	19,385,755	10.782	-310,067	3,345,524

Biggest Buyers First

House Positions for C:APH from 20180801 to 20180801

House	Bought	$Val	Ave	Sold	$Val	Ave	Net	$Net
7 TD Sec	1,534,357	16,581,012	10.806	847,978	9,173,172	10.818	686,379	-7,407,840
2 RBC	647,716	6,984,497	10.783	486,691	5,255,943	10.799	161,025	-1,728,554
85 Scotia	521,294	5,631,525	10.803	457,570	4,943,965	10.805	63,724	-687,560
9 BMO Nesbitt	281,390	3,035,026	10.786	229,178	2,469,806	10.777	52,212	-565,220
58 Qtrade	59,414	644,959	10.855	20,825	226,208	10.862	38,589	-418,751
124 Questrade	240,202	2,601,487	10.83	208,908	2,262,532	10.83	31,294	-338,955
101 SG Capital	23,700	257,034	10.845	4,800	52,821	11.004	18,900	-204,213
22 Fidelity	45,656	491,367	10.762	30,418	329,773	10.841	15,238	-161,594
15 UBS	13,040	140,859	10.802	1,150	12,353	10.742	11,890	-128,506
59 PI	7,419	81,109	10.933	43	463	10.767	7,376	-80,646
99 Jitney	89,700	974,108	10.86	83,000	903,429	10.885	6,700	-70,679
28 BBS	58,208	628,016	10.789	52,730	571,032	10.829	5,478	-56,984
14 ITG	5,881	63,257	10.756	1,625	17,294	10.642	4,256	-45,963
94 Hampton	2,417	26,160	10.823	0			2,417	-26,160
65 Goldman	1,600	16,926	10.579	27	298	11.037	1,573	-16,628
48 Laurentian	1,470	15,768	10.727	0			1,470	-15,768
19 Desjardins	43,206	467,306	10.816	42,174	456,565	10.826	1,032	-10,741
76 Industrial Alliance	874	9,343	10.69	400	4,392	10.98	474	-4,951
56 Edward Jones	660	7,055	10.689	200	2,122	10.61	460	-4,933
70 Manulife	3,200	34,006	10.627	2,900	30,623	10.56	300	-3,383
88 Credential	2,080	22,697	10.912	3,273	35,466	10.836	-1,193	12,769
36 Latimer	2,050	22,071	10.766	3,369	36,344	10.788	-1,319	14,273
57 Interactive	2,061	22,263	10.802	3,384	36,751	10.86	-1,323	14,488
143 Pershing	19,056	205,094	10.763	20,656	223,574	10.824	-1,600	18,480
87 Beacon	0			1,700	18,530	10.90	-1,700	18,530
90 Barclays	2,000	21,906	10.953	4,400	46,928	10.665	-2,400	25,022
80 National Bank	83,816	903,897	10.784	87,602	952,038	10.868	-3,786	48,141
72 Credit Suisse	100	1,068	10.68	6,400	69,794	10.905	-6,300	68,726
89 Raymond James	120,680	1,301,961	10.789	152,622	1,651,982	10.824	-31,942	350,021
74 GMP	0			63,206	682,907	10.804	-63,206	682,907
13 Instinet	93,365	1,006,039	10.775	168,600	1,820,779	10.799	-75,235	814,740
33 Canaccord	96,229	1,042,865	10.837	172,305	1,873,496	10.873	-76,076	830,631
39 Merrill Lynch	167,646	1,811,309	10.804	267,261	2,878,360	10.77	-99,615	1,067,051
1 Anonymous	1,342,981	14,529,231	10.819	1,486,220	16,055,849	10.803	-143,239	1,526,618
53 Morgan Stanley	28,502	307,507	10.789	326,715	3,516,482	10.763	-298,213	3,208,975
79 CIBC	1,429,339	15,417,453	10.786	1,732,979	18,694,110	10.787	-303,640	3,276,657
TOTAL	6,971,309	75,306,181	10.802	6,971,309	75,306,181	10.802	0	0

Molson Coors Canada enters cannabis sector with Hydropothecary partnership

TORONTO — Molson Coors Canada, the business arm of Molson Coors Brewing Co., says it has entered into a joint venture to develop non-alcoholic, cannabis-infused beverages.

Recreational marijuana is set to become legal in Canada on Oct.17, but edible products infused with pot will remain illegal until specific government regulations are rolled out in 2019 at the earliest.

The brewer says the venture with The Hydropothecary Corporation (HEXO) will be a standalone start-up with its own board and management team, with Molson Coors Canada having a 57.5 per cent interest and HEXO holding the balance.

The joint venture is subject to various approvals conditions and is scheduled to close before Sept. 30.

HEXO, based in Gatineau, Que., currently has more than 300,000 square feet of production capacity with an expansion more than three times that size to be completed by the end of the year.

“While we remain a beer business at our core, we are excited to create a separate new venture with a trusted partner that will be a market leader in offering Canadian consumers new experiences with quality, reliable and consistent non-alcoholic, cannabis-infused beverages,” said Molson Coors Canada president and CEO Frederic Landtmeters.

“Molson Coors Canada has a unique opportunity to participate in this exciting and rapidly expanding consumer segment,” he said.

“We are excited about this partnership with Molson Coors Canada … as we embark on the journey of building a brand new market,” added HEXO CEO and co-founder Sebastien St-Louis.

APHRIA Loss 6 cents per share ouch...and no Molson Deal

Look out below...we cashed out yesterday didn't want to gamble on financials ...
this could open 1.00 cheaper OUCH

Aphria Records Revenue Increase of 17% in Quarter and 81% Year Over Year

Canada NewsWire

LEAMINGTON, ON, Aug. 1, 2018

Adjusted gross margin increases to 78.7% of revenue as cash costs per gram remain below $1.00Industry leading eleventh consecutive quarter of positive Adjusted EBITDA from ACMPR operations¹

LEAMINGTON, ON, Aug. 1, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH or USOTCQB: APHQF) today reported its results, for the fourth quarter and year ended May 31, 2018. All amounts are expressed in Canadian dollars.

Three months ended May 31,			Twelve months ended May 31,
2018	2017		2018	2017
$ 12,026	$ 5,718	Revenue	$ 36,917	$ 20,438
$ 18,591	$ 5,826	Gross profit	$ 40,877	$ 17,298
$ 9,468	$ 4,903	Adjusted gross profit 1	$ 27,912	$ 15,854
78.7%	85.7%	Adjusted gross margin 1	75.6%	77.6%
$ (4,992)	$ (2,593)	Net income (loss)	$ 29,448	$ 4,198
$ 2,227	$ 2,534	Adjusted EBITDA from ACMPR operations 1	$ 8,419	$ 5,517
Q4-2018				Q3-2018
1,312.6		Kilograms (or kilogram equivalents) sold 1		1,428.1
$ 12,026		Revenue		$ 10,267
$ 2,227		Adjusted EBITDA from ACMPR operations 1		$ 2,940
$ 0.95		Cash cost to produce dried cannabis / gram 1		$ 0.96
$ 1.60		"All-in" cost of goods sold / gram1		$ 1.56
$ 104,799		Cash and cash equivalents & marketable securities		$ 173,683
$ 150,758		Working capital		$ 234,589
$ 39,042		Investment in capital and intangible assets – wholly-owned subs 1		$ 35,427

Key Operating Highlights

• Eleventh consecutive quarter of positive Adjusted EBITDA from ACMPR operations¹. $2.2 million in adjusted EBITDA from ACMPR operations¹ in the quarter and $8.4 million for the year, a 38% increase over the prior year.
• Improved cash costs to produce dried cannabis per gram¹ ("Cash costs") to $0.95, a decrease of $0.01 in the quarter, remaining below $1.00 for the second consecutive quarter.
• International operations and presence increased from Canada, US and Australia to also include Germany, Malta, Lesotho, Italy, Colombia, Argentina, United Kingdom and Uruguay. Subsequent to year-end, announced access to additional countries including Jamaica and Brazil in the fall.
• Annual production capacity in Canada currently at 30,000 kgs at Aphria One and 5,000 kgs at Broken Coast.
• Annual production capacity in Canada growing to 255,000 kgs, with first sale expected in January 2019, all expansions remain on time, pending Health Canada approval, and on budget.
• Secured partnership with one of North America's largest liquor distributors, Southern Glazer's through their Canadian subsidiary, Great North Distributors, providing Aphria with an exclusive for cannabis representation²
• Signed MOU's with British Columbia, Alberta, Manitoba, Quebec, New Brunswick and the Yukon Territory, with more agreements to be announced in the short-term.
• Added significantly to our senior leadership team with the hire of our Chief Commercial Officer and Chief Legal Officer.
• Continued leadership in cannabis product innovation with announcement of a major investment in our Extraction Centre of Excellence.

"We had a healthy fourth quarter and a solid year with many achievements we are proud of," said Vic Neufeld, Chief Executive Officer, Aphria. "We are excited and ready to hit the ground running on the first day of legal adult-use. It won't be without its challenges but we have a plan and the team in place to get it done. We continue to sign supply agreements with provinces and territories, and our Southern Glazer's sales network partnership is unmatched, ensuring our brands and products are available and represented by retailers across the country."

"Beyond that, we will continue to extend our industry-leading expertise and experience into global markets. We've had an exciting year adding more depth and experience to our senior leadership team that has helped expand our international operations and presence outside of Canada, US and Australia to an additional eight countries, and look forward to continued expansion within LATAM," continued Neufeld.

"Our continued growth and success is a direct result of the hard work and dedication of our employees and partners in delivering quality product and value to our patients, and establishing Aphria as the premier cannabis company in Canada and around the world," concluded Neufeld.

Key Financial Highlights

For an industry leading eleventh consecutive quarter, the Company reported positive adjusted EBITDA from ACMPR operations¹. In the quarter, the Company reported $2.2 million in adjusted EBITDA from ACMPR operations¹ and $8.4 million for the year, an increase of 53%. During the quarter, the Company refined its definition of adjusted EBITDA to include an EBITDA definition from both ACMPR operations and non-ACMPR operations. The Company defines ACMPR operations as activities, revenue, expenses and adjusted EBITDA from its Aphria One, Aphria Diamond and Broken Coast facilities. The remaining adjusted EBITDA relates to activities at Aphria International. For the quarter ended, the Company incurred an adjusted EBITDA loss of $2.8 million at Aphria International.

The Company remains committed to the responsible use of our shareholders' investment in Aphria, with a focus on profitable execution of our activities. The Company has consistently demonstrated the proven ability to generate positive EBITDA from its operating facilities. As the cannabis industry and the Company transitions from medical use to adult-use in Canada and to significant international exposure, the Company will continue to make targeted, measured and ROI proven investments in its growing portfolio of recreational brands, alternate uses of cannabis, including the transition of cannabis from a product to an ingredient, and international opportunities. However, in the short-term, investments could result in lower corporate adjusted EBITDA¹.

During the quarter, the Company bolstered its position as one of the industry's lowest cost producers. For the second consecutive quarter, the Company reported Cash costs of $0.95, remaining below $1.00. As previously disclosed, the Company's "All-in" costs of dried cannabis per gram¹ ("All-in costs") increased minorly from $1.56 to $1.60, costs consistent with the additional staff levels added in advance of production capacity increases in the quarter.

The Company believes in full financial reporting transparency to shareholders and will continue to report financial metrics with an appropriate base of grams, or kilograms where relevant, to ensure shareholders are capable of properly comparing metrics amongst industry participants. Further, when reporting non-IFRS measures, the Company will continue to provide detailed disclosure, and transparency tied to its released financial statements.

Revenue for the three months ended May 31, 2018 was $12,026, representing a 17% increase over the prior quarter's revenue of $10,267. The increase in the quarter was driven primarily by reporting Broken Coast results for a full quarter, compared to one month in the prior quarter, increased sales to medical patients at Aphria, all offset by the Company's previously announced decision to discontinue wholesales sales to other licensed producers, to provide increased inventory for the eventual pipeline fill for adult-use and international market opportunities over the next six to nine months. Cannabis oil sales, as a percentage of volume, decreased from 33.1% to 29.2% in the quarter, largely driven by the significantly lower percentage of volume sales of oil purchased by Broken Coast medical patients.

For the year ended May 31, 2018, revenue was $36,917 versus $20,438 in the year ended May 31, 2017, an increase of 81%.

Adjusted gross profit for the fourth quarter was $9,468, with an adjusted gross margin of 78.7%, compared to $4,903 with an adjusted gross margin of 85.7% in the prior year's fourth quarter, representing an increase of over 90%. The increase in the adjusted gross margin from the prior quarter is consistent with the increase in revenues combined with improved cost structures.

Adjusted gross profit for the year was $27,912, with an adjusted gross margin of 75.6%, compared to $15,854, with an adjusted gross margin of 77.6%, representing an increase of over 75%. The increase in adjusted gross profit for the year is consistent with the Company's increase in revenue over the period.

Net loss for the three months ended May 31, 2018 was $4,992 or $0.06 per share, as opposed to a net loss of $2,593 or $0.02 per share in the prior year. The decrease in net income for the quarter relates to $6.5 million in incremental share based compensation, $3.3 million of costs associated with Aphria International, $8.6 million in net losses on the Company's investment portfolio, all offset by almost $13.0 million in incremental gross profit.

Net income for the year ended May 31, 2018 was $29,448 or $0.18 per share, as opposed to $4,198 or $0.04 in the prior year. The increase in net income for the year relates to fair value adjustments associated with biological assets and unrealized gains on the Company's investment portfolio.

Adjusted EBITDA from ACMPR operations¹ for the fourth quarter was $2.2 million compared to $2.5 million in the prior year. The decrease in adjusted EBITDA from ACMPR operations¹ relates to $1.9 million in incremental selling, general and administrative expenses associated with preparations for adult-use, offset by $1.5 million of additional adjusted gross profit¹. Adjusted EBITDA¹ loss for the fourth quarter was $0.6 million, compared to adjusted EBITDA¹ of $2.5 million in the prior year. The difference between adjusted EBITDA from ACMPR operations and adjusted EBITDA¹ is the $2.8 million adjusted EBITDA¹ loss on Aphria International operations.

Adjusted EBITDA from ACMPR operations¹ for the year ended May 31, 2018 was $8.4 million compared to $5.5 million in the prior year, an increase of 53%. The increase in adjusted EBITDA from ACMPR operations¹ relates to capacity increases at Aphria One, the acquisition of Broken Coast offset by larger selling, general and administrative expenses. Adjusted EBITDA¹ for the year was $5.6 million compared to $5.5 million in the prior year.

Conference Call On August 1, 2018

The Company invites you to join its analyst conference call on Wednesday, August 1, 2018 at 9:00 am EST to discuss its financial results for the quarter-ended and year ended May 31, 2018. An audio replay of this call will be available until September 1, 2018.

Conference Call Details:
Date:	Wednesday, August 1, 2018
Time:	9:00 am EST
Dial In:	1-888-231-8191
Conference ID:	1886434
Replay:	1-855-859-2056
Replay Passcode:	1886434

We Have A Good Thing Growing.

1 – In this press release, reference is made to adjusted gross profit, adjusted gross margin, adjusted EBITDA from ACMPR operations, kilogram (or kilogram equivalents) sold, cash costs to produce dried cannabis per gram, "all-in" costs to produce dried cannabis per gram and investments in capital and intangible assets – wholly-owned subs, which are not measures of financial performance under International Financial Reporting Standards. Definitions for all terms above can be found in the Company's May 31, 2018 Management's Discussion and Analysis, filed on SEDAR.

2 – Aphria maintains a cannabis exclusive with Great North Distributors for licensed producers with annual production capacities above 2,000 kgs.

About Aphria

Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company's portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders' multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

For more information, visit aphria.ca.